PTGIR and pulmonary arterial hypertension: Moreover, it could enhance the production of cyclic adenosine monophosphate (cAMP), suggesting that cefminox has a promising potential in the treatment of pulmonary hypertension, as it targets prostacyclin receptor and PPAR-γ [144].